In the BioHarmony Drug Report Database

"Preview" Icon

Necitumumab

Portrazza (necitumumab) is an antibody pharmaceutical. Necitumumab was first approved as Portrazza on 2015-11-24. It is used to treat non-small-cell lung carcinoma in the USA. The pharmaceutical is active against epidermal growth factor receptor.

 

Trade Name

 

Portrazza
 

Common Name

 

necitumumab
 

ChEMBL ID

 

CHEMBL1743047
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Necitumumab structure rendering